OnCo
technologiesTechnologyEstablished

Circulating tumour HPV DNA (ctHPV-DNA)

A blood test that detects fragments of the virus DNA shed by HPV-positive throat cancers, to confirm diagnosis, track response, and catch recurrence early.

Digital droplet PCR or NGS assays (NavDx, others) detect HPV16 DNA in plasma with high specificity; clearance during chemoradiation predicts cure and post-treatment surveillance detects recurrence months before imaging. Being used to select patients for response-adapted de-escalation after the failure of HPV-status-alone selection (NRG-HN005).

Generic schematic · not to scale · placeholder for the diagnostics front
Molecular read-out

How it works

Tumour-tissue-modified viral DNA fragments quantified in cell-free plasma DNA.

Strengths
  • Highly specific to the tumour
  • Cheap, repeatable, earlier than imaging
Limitations
  • Only for HPV-driven disease
  • Interventional trials proving benefit of acting on it are ongoing

Latest papers

top
Literature trend20 papers in the last 12 months+122% vs prior 12How this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Circulating tumour HPV DNA" OR ABSTRACT:"Circulating tumour HPV DNA" OR TITLE:"ctHPV-DNA" OR ABSTRACT:"ctHPV-DNA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Circulating tumour HPV DNA (ctHPV-DNA), not a curated reading list.

Connected

12top

Pages like this

not linked directly; found by shared links